Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma.

Abstract

The goal of this study was to evaluate the anti-tumour activity and toxicoses of vinorelbine as a palliative rescue therapy for dogs with primary urinary bladder carcinoma. Thirteen dogs refractory to prior chemotherapeutics and one dog naïve to chemotherapeutic treatment were enrolled. Vinorelbine (15 mg m(-2) IV) was administered intravenously along with concurrent oral anti-inflammatory drugs, if tolerated. A median of six doses of vinorelbine (range: 1-16) was administered. Two dogs (14%) had partial responses, and eight (57%) experienced stable disease. Subjective improvement in clinical signs was noted in 11 dogs (78%). Adverse events were mild and primarily haematological in nature. Median time to progression was 93 days (range: 20-239 days). Median survival time for all dogs was 187 days; median survival for 13 pre-treated dogs was 207 days. Vinorelbine may have utility in the management of canine primary urinary bladder carcinoma and should be evaluated in a prospective study.

• Authors: M E Kaye, D H Thamm, K Weishaar, J A Lawrence
• Journal: Veterinary and comparative oncology (Vet Comp Oncol) Vol. 13 Issue 4 Pg. 443-51 (Dec 2015) ISSN: 1476-5829 [Electronic] England
• PMID: 23981116 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2013 John Wiley & Sons Ltd.

Chemical References

• Antineoplastic Agents, Phytogenic
• Vinblastine
• Vinorelbine

Topics

• Animals
• Antineoplastic Agents, Phytogenic (adverse effects, therapeutic use)
• Dog Diseases (drug therapy, mortality)
• Dogs
• Drug Administration Schedule (veterinary)
• Drug Repositioning (veterinary)
• Female
• Male
• Survival Analysis
• Urinary Bladder Neoplasms (drug therapy, mortality, veterinary)
• Vinblastine (adverse effects, analogs & derivatives, therapeutic use)
• Vinorelbine